Background Patients with type 2 diabetes mellitus (T2DM) are prone to develop non-
alcoholic fatty liver disease (NAFLD) and cardiovascular diseases (CVD). We aimed to …

We performed the largest randomized, placebo‐controlled clinical trial to date (N= 112, 12‐
week intervention) to investigate the effects and safety of resveratrol supplementation on …

Introduction: Cardiovascular disease (CVD) accounts as a major cause of mortality among
patients with nonalcoholic fatty liver disease (NAFLD). Resveratrol, a natural polyphenol …

Non-alcoholic fatty liver disease (NAFLD) is usually associated with insulin resistance,
central obesity, reduced glucose tolerance, type 2 diabetes mellitus and …

The present study (NCT01446276, ClinicalTrials. gov) assessed long‐term effects of high‐
dose Resveratrol (RSV) on basal and insulin‐mediated very low‐density lipoprotein …

Background There are current trials investigating the effect of resveratrol supplementation
on lipid profiles and liver enzymes among patients with metabolic syndrome (MetS) and …

Objective Few studies have considered the effect of resveratrol on blood lipid levels, and the
results of these studies are inconsistent. In this study, the first meta‐analysis on the effect of …

The aim of the present randomized controlled trial was to evaluate the effect of a micronized
resveratrol supplement on glycemic status, lipid profile, and body composition in patients …

Background In vitro and animal studies have shown positive effects of resveratrol on lipid
and lipoprotein metabolism, but human studies specifically designed to examine these …

Background Non-alcoholic fatty liver disease is a major health problem worldwide.
Resveratrol is a natural polyphenol found in edible plants that has a variety of biochemical …